SE8801903L - PHOSPHORETIC HMG COA REDUCTION INHIBITOR, NEW INTERMEDIATE AND SET - Google Patents
PHOSPHORETIC HMG COA REDUCTION INHIBITOR, NEW INTERMEDIATE AND SETInfo
- Publication number
- SE8801903L SE8801903L SE8801903A SE8801903A SE8801903L SE 8801903 L SE8801903 L SE 8801903L SE 8801903 A SE8801903 A SE 8801903A SE 8801903 A SE8801903 A SE 8801903A SE 8801903 L SE8801903 L SE 8801903L
- Authority
- SE
- Sweden
- Prior art keywords
- compounds
- phosphoretic
- hmg coa
- new intermediate
- reduction inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
- C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
- C07F9/36—Amides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/44—Amides thereof
- C07F9/4403—Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4407—Amides of acyclic saturated acids which can have further substituents on alkyl
Abstract
Compounds which are useful as inhibitors of cholesterol biosynthesis and thus as hypocholesterolemic agents have the structure <IMAGE> including salts thereof, wherein R is OH, lower alkoxy or lower alkyl; R<x> is H or alkyl; X is -O- or -NH-; n is 1 or 2 Z is a hydrophobic anchor, such as <IMAGE> wherein the dotted lines represent optional double bonds. New intermediates used in preparing the above compounds, e.g. compounds in which the OH group is silane blocked, pharmaceutical compositions containing such compounds and a method for using such compounds to inhibit cholesterol biosynthesis are also provided.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5328187A | 1987-05-22 | 1987-05-22 | |
US10968087A | 1987-10-19 | 1987-10-19 |
Publications (3)
Publication Number | Publication Date |
---|---|
SE8801903D0 SE8801903D0 (en) | 1988-05-20 |
SE8801903L true SE8801903L (en) | 1988-11-23 |
SE503210C2 SE503210C2 (en) | 1996-04-22 |
Family
ID=26731667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE8801903A SE503210C2 (en) | 1987-05-22 | 1988-05-20 | Phosphorus-containing HMG-CoA-Reductase Inhibitor, New Intermediates and Methods |
Country Status (24)
Country | Link |
---|---|
JP (1) | JP2680347B2 (en) |
KR (1) | KR880013958A (en) |
CN (1) | CN88103091A (en) |
AU (1) | AU610591B2 (en) |
BE (1) | BE1004193A3 (en) |
CH (1) | CH676984A5 (en) |
DE (1) | DE3817375C2 (en) |
DK (1) | DK277488A (en) |
ES (1) | ES2009918A6 (en) |
FI (1) | FI89493C (en) |
FR (1) | FR2615508B1 (en) |
GB (1) | GB2205837B (en) |
GR (1) | GR1000959B (en) |
HU (1) | HU205125B (en) |
IE (2) | IE63760B1 (en) |
IL (1) | IL86464A (en) |
IT (1) | IT1217685B (en) |
NL (1) | NL8801330A (en) |
NO (1) | NO882218L (en) |
NZ (1) | NZ224733A (en) |
PH (1) | PH25350A (en) |
PL (1) | PL154877B1 (en) |
PT (1) | PT87539B (en) |
SE (1) | SE503210C2 (en) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK277388A (en) * | 1987-05-22 | 1988-11-23 | Squibb & Sons Inc | PHOSPHORUS HMG-COA REDUCTASE INHIBITORS, INTERMEDIATES AND PROCEDURE |
CA2007643A1 (en) * | 1989-02-01 | 1990-08-01 | Donald S. Karanewsky | Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination |
CA2042526A1 (en) * | 1990-06-11 | 1991-12-12 | Adeoye Y. Olukotun | Method for preventing a second heart attack employing an hmg coa reductase inhibitor |
US5202327A (en) * | 1991-07-10 | 1993-04-13 | E. R. Squibb & Sons, Inc. | Phosphorus-containing hmg-coa reductase inhibitors |
GB9126144D0 (en) * | 1991-12-10 | 1992-02-12 | British Bio Technology | Compounds |
US20010006644A1 (en) | 1997-07-31 | 2001-07-05 | David J. Bova | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
SK3202001A3 (en) | 1998-09-17 | 2002-04-04 | Bristol Myers Squibb Co | Drug and a pharmaceutical composition for treating diabetes, insulin resistance, obesity, hyperglycemia, hyperinsulinemia or increased level |
HUP0600232A2 (en) | 2001-04-11 | 2006-08-28 | Bristol Myers Squibb Co | Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
GEP20063908B (en) | 2001-10-18 | 2006-08-25 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
US7238671B2 (en) | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
US6806381B2 (en) | 2001-11-02 | 2004-10-19 | Bristol-Myers Squibb Company | Process for the preparation of aniline-derived thyroid receptor ligands |
US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
EP1553937B1 (en) | 2002-10-23 | 2010-06-02 | Bristol-Myers Squibb Company | Glycinenitrile-based inhibitors of dipeptidyl peptidase iv |
US7098235B2 (en) | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
TW200504021A (en) | 2003-01-24 | 2005-02-01 | Bristol Myers Squibb Co | Substituted anilide ligands for the thyroid receptor |
US7459474B2 (en) | 2003-06-11 | 2008-12-02 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
US6995183B2 (en) | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
US8158362B2 (en) | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
DK1725234T4 (en) | 2004-03-05 | 2016-05-09 | Univ Pennsylvania | METHODS OF TREATING DISEASES OR DISEASES CONNECTED WITH HYPERLIPIDEMIA AND HYPERCOLESTEROLYMIA WITH MINIMIZATION OF SIDE EFFECTS |
TW200611704A (en) | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
US7145040B2 (en) | 2004-07-02 | 2006-12-05 | Bristol-Myers Squibb Co. | Process for the preparation of amino acids useful in the preparation of peptide receptor modulators |
US7534763B2 (en) | 2004-07-02 | 2009-05-19 | Bristol-Myers Squibb Company | Sustained release GLP-1 receptor modulators |
AR051446A1 (en) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | C-ARYL GLUCOSIDS AS SELECTIVE INHIBITORS OF GLUCOSE CONVEYORS (SGLT2) |
US7517991B2 (en) | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
US7635699B2 (en) | 2004-12-29 | 2009-12-22 | Bristol-Myers Squibb Company | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
US7589088B2 (en) | 2004-12-29 | 2009-09-15 | Bristol-Myers Squibb Company | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
US7361766B2 (en) | 2005-01-12 | 2008-04-22 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
US7314882B2 (en) | 2005-01-12 | 2008-01-01 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
WO2006076597A1 (en) | 2005-01-12 | 2006-07-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
US20060160850A1 (en) | 2005-01-18 | 2006-07-20 | Chongqing Sun | Bicyclic heterocycles as cannabinoid receptor modulators |
WO2006113261A2 (en) | 2005-04-14 | 2006-10-26 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
US7521557B2 (en) | 2005-05-20 | 2009-04-21 | Bristol-Myers Squibb Company | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods |
US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
US7629342B2 (en) | 2005-06-17 | 2009-12-08 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
US7317012B2 (en) | 2005-06-17 | 2008-01-08 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoind-1 receptor modulators |
TW200726765A (en) | 2005-06-17 | 2007-07-16 | Bristol Myers Squibb Co | Triazolopyridine cannabinoid receptor 1 antagonists |
US8618115B2 (en) | 2005-10-26 | 2013-12-31 | Bristol-Myers Squibb Company | Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them |
WO2007053819A2 (en) | 2005-10-31 | 2007-05-10 | Bristol-Myers Squibb Company | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods |
US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US7553836B2 (en) | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
US20100022457A1 (en) | 2006-05-26 | 2010-01-28 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
WO2008057862A2 (en) | 2006-11-01 | 2008-05-15 | Bristol-Myers Squibb Company | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF |
AR065809A1 (en) | 2007-03-22 | 2009-07-01 | Bristol Myers Squibb Co | PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR |
PE20090696A1 (en) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | CRYSTALLINE FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING THEM |
WO2009023059A2 (en) | 2007-06-01 | 2009-02-19 | The Trustees Of Princeton University | Treatment of viral infections by modulation of host cell metabolic pathways |
US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
EP2173717B9 (en) | 2007-07-27 | 2013-06-26 | Bristol-Myers Squibb Company | Novel glucokinase activators and methods of using same |
NZ583495A (en) | 2007-09-20 | 2011-11-25 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
PE20091928A1 (en) | 2008-05-29 | 2009-12-31 | Bristol Myers Squibb Co | HAVE HYDROXYSUSTITUTED PYRIMIDINES AS NON-BASIC MELANIN-CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS |
CA2756786A1 (en) | 2009-03-27 | 2010-09-30 | Bristol-Myers Squibb Company | Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors |
WO2011014520A2 (en) | 2009-07-29 | 2011-02-03 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
BR112012008004A2 (en) | 2009-10-09 | 2016-03-29 | Irm Llc | compounds and compositions as modulators of gpr119 activity |
MX2012005425A (en) | 2009-11-13 | 2012-06-14 | Astrazeneca Uk Ltd | Reduced mass metformin formulations. |
CA3002948C (en) | 2009-11-13 | 2020-10-27 | Astrazeneca Uk Limited | Immediate release tablet formulations |
WO2011060256A2 (en) | 2009-11-13 | 2011-05-19 | Bristol-Myers Squibb Company | Bilayer tablet formulations |
US8394858B2 (en) | 2009-12-03 | 2013-03-12 | Novartis Ag | Cyclohexane derivatives and uses thereof |
TWI562775B (en) | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
EP2558461B1 (en) | 2010-04-14 | 2015-12-02 | Bristol-Myers Squibb Company | Novel glucokinase activators and methods of using same |
MX342120B (en) | 2010-07-09 | 2016-09-14 | William Owen Wilkison | Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin. |
US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
TWI631963B (en) | 2011-01-05 | 2018-08-11 | 雷西肯製藥股份有限公司 | Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
WO2014052619A1 (en) | 2012-09-27 | 2014-04-03 | Irm Llc | Piperidine derivatives and compositions as modulators of gpr119 activity |
ES2869286T3 (en) | 2012-11-20 | 2021-10-25 | Lexicon Pharmaceuticals Inc | Sodium-glucose cotransporter 1 inhibitors |
WO2015027021A1 (en) | 2013-08-22 | 2015-02-26 | Bristol-Myers Squibb Company | Imide and acylurea derivatives as modulators of the glucocorticoid receptor |
CN104610262B (en) * | 2013-11-01 | 2017-06-06 | 上海医药工业研究院 | Biphenyl compound, intermediate, preparation method, pharmaceutical composition and its application |
KR20170138570A (en) | 2015-04-30 | 2017-12-15 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Anti-aP2 antibodies and antigen binding substances for the treatment of metabolic disorders |
CR20210029A (en) | 2018-07-19 | 2021-02-26 | Astrazeneca Ab | Methods of treating hfpef employing dapagliflozin and compositions comprising the same |
SG11202102498UA (en) | 2018-09-26 | 2021-04-29 | Lexicon Pharmaceuticals Inc | Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA828650B (en) * | 1981-12-01 | 1983-09-28 | Hunt Chem Corp Philip A | Herbicidal compositions and method using phosphonalkanoic acids, esters and salts thereof |
FR2596393B1 (en) * | 1986-04-01 | 1988-06-03 | Sanofi Sa | HYDROXY-3 DIHYDROXYOXOPHOSPHORIO-4 BUTANOIC ACID DERIVATIVES, THEIR PREPARATION PROCESS, THEIR USE AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM |
DK277388A (en) * | 1987-05-22 | 1988-11-23 | Squibb & Sons Inc | PHOSPHORUS HMG-COA REDUCTASE INHIBITORS, INTERMEDIATES AND PROCEDURE |
-
1988
- 1988-05-20 DK DK277488A patent/DK277488A/en not_active Application Discontinuation
- 1988-05-20 NO NO882218A patent/NO882218L/en unknown
- 1988-05-20 PT PT87539A patent/PT87539B/en not_active IP Right Cessation
- 1988-05-20 DE DE3817375A patent/DE3817375C2/en not_active Expired - Fee Related
- 1988-05-20 GB GB8811929A patent/GB2205837B/en not_active Expired - Fee Related
- 1988-05-20 NZ NZ224733A patent/NZ224733A/en unknown
- 1988-05-20 SE SE8801903A patent/SE503210C2/en not_active IP Right Cessation
- 1988-05-20 ES ES8801610A patent/ES2009918A6/en not_active Expired
- 1988-05-20 IE IE154388A patent/IE63760B1/en not_active IP Right Cessation
- 1988-05-20 GR GR880100331A patent/GR1000959B/en unknown
- 1988-05-20 IL IL86464A patent/IL86464A/en not_active IP Right Cessation
- 1988-05-20 IT IT20682/88A patent/IT1217685B/en active
- 1988-05-20 AU AU16508/88A patent/AU610591B2/en not_active Ceased
- 1988-05-20 FI FI882384A patent/FI89493C/en not_active IP Right Cessation
- 1988-05-20 PH PH36956A patent/PH25350A/en unknown
- 1988-05-20 IE IE930324A patent/IE930324L/en unknown
- 1988-05-20 HU HU882614A patent/HU205125B/en not_active IP Right Cessation
- 1988-05-21 PL PL1988272597A patent/PL154877B1/en unknown
- 1988-05-21 CN CN198888103091A patent/CN88103091A/en active Pending
- 1988-05-21 KR KR1019880006020A patent/KR880013958A/en not_active Application Discontinuation
- 1988-05-21 JP JP63124809A patent/JP2680347B2/en not_active Expired - Lifetime
- 1988-05-24 BE BE8800566A patent/BE1004193A3/en not_active IP Right Cessation
- 1988-05-24 NL NL8801330A patent/NL8801330A/en not_active Application Discontinuation
- 1988-05-24 FR FR8806885A patent/FR2615508B1/en not_active Expired - Fee Related
- 1988-05-24 CH CH1967/88A patent/CH676984A5/fr not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE8801903L (en) | PHOSPHORETIC HMG COA REDUCTION INHIBITOR, NEW INTERMEDIATE AND SET | |
EE03194B1 (en) | Compounds, their use as sweetening agents and process for their preparation | |
SE8801904D0 (en) | PHOSPHORETIC HMG-COA REDUCTION INHIBITORS, NEW INTERMEDIATES AND METHOD | |
EP0324421A3 (en) | Phosporus-containing squalene synthetase inhibitors, new intermediates and method | |
DK271287A (en) | TRANS-6- (2- (3- OR 4-CARBOXAMIDO-SUBSTITUTED PYRROL-1-YL) ALKYL) -4-HYDROXYPYRAN-2-ONES, THEIR PREPARATION AND PHARMACEUTICAL USE | |
FI855117A0 (en) | Segmented polyesters and similar compounds for use as soil release agents in detergent compositions | |
RU93050199A (en) | DEOXITAXOLS, METHODS OF THEIR PRODUCTION, INTERMEDIATE COMPOUNDS, PHARMACEUTICALS | |
ES2066140T3 (en) | DERIVATIVES OF 7-CETO- AND 7-HYDROXY-ANDROSTA-3,5-DIENO-3-CARBOXYLIC ACIDS. | |
DK438887D0 (en) | PROCEDURE FOR THE PREPARATION OF CHEMICAL COMPOUNDS | |
DE58907920D1 (en) | New alkanophenones. | |
EP0245990A3 (en) | Antihypercholesterolemic compounds | |
EP0108547A3 (en) | 1-bromoethyl ethyl carbonate and its use in the preparation of 1'-ethoxy-carbonyloxyethyl esters of penicillins and novel intermediates, methods for its preparation and 1-bromoethylchloroformate and 1-bromoethylbromoformate obtained as intermediates | |
IE790771L (en) | 1,2-disubstituted pyrrolidine and piperidine compounds. | |
CA1267906C (en) | 7-oxabicycloheptane substituted prostaglandin analogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NUG | Patent has lapsed |